|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.120 EUR | +2.28% |
|
+5.42% | +10.81% |
| 02-03 | Global markets live: SpaceX, Tesla, Boeing, PayPal, AstraZeneca… | |
| 02-03 | Valneva, Instituto Butantan Start Pilot Program for Chikungunya Vaccine in Brazil | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -9.65 | -6.31 | -9.87 | -10.23 | -10.03 | |||||
Return on Total Capital | -17.08 | -17.08 | -21.6 | -15.59 | -13.11 | |||||
Return On Equity % | -60.58 | -59.21 | -73.41 | -58.29 | -7.91 | |||||
Return on Common Equity | -60.58 | -59.21 | -73.41 | -58.29 | -7.91 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -25.77 | -3.77 | -18.84 | -4.59 | -1.83 | |||||
SG&A Margin | 41.6 | 20.57 | 15.94 | 62.81 | 56.08 | |||||
EBITDA Margin % | -46.47 | -16.16 | -27.56 | -49.91 | -36.77 | |||||
EBITA Margin % | -49.96 | -18.37 | -31.44 | -57.55 | -45.44 | |||||
EBIT Margin % | -49.96 | -18.37 | -31.44 | -57.55 | -45.44 | |||||
Income From Continuing Operations Margin % | -58.37 | -21.09 | -39.66 | -65.99 | -7.22 | |||||
Net Income Margin % | -58.37 | -21.09 | -39.66 | -65.99 | -7.22 | |||||
Net Avail. For Common Margin % | -58.37 | -21.09 | -39.66 | -65.99 | -7.22 | |||||
Normalized Net Income Margin | -36.99 | -13.02 | -25.08 | -42.7 | -37.55 | |||||
Levered Free Cash Flow Margin | 47.86 | -11 | -37.98 | -125.66 | -48.95 | |||||
Unlevered Free Cash Flow Margin | 53.94 | -7.96 | -34.68 | -116.18 | -40.11 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.31 | 0.55 | 0.5 | 0.28 | 0.35 | |||||
Fixed Assets Turnover | 1.5 | 2.76 | 2.2 | 0.99 | 1.08 | |||||
Receivables Turnover (Average Receivables) | 5.1 | 1.99 | 3.38 | 4.41 | 4.25 | |||||
Inventory Turnover (Average Inventory) | 5.27 | 4.78 | 5.39 | 4.04 | 3.52 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.75 | 1.59 | 1.53 | 1.65 | 2.61 | |||||
Quick Ratio | 1.27 | 1.06 | 1.13 | 1.06 | 1.78 | |||||
Operating Cash Flow to Current Liabilities | 0.78 | 0.21 | -0.88 | -1.28 | -0.59 | |||||
Days Sales Outstanding (Average Receivables) | 71.76 | 183.26 | 107.98 | 82.73 | 86.15 | |||||
Days Outstanding Inventory (Average Inventory) | 69.51 | 76.31 | 67.67 | 90.33 | 103.99 | |||||
Average Days Payable Outstanding | 44.16 | 16.3 | 16.37 | 34.4 | 30.39 | |||||
Cash Conversion Cycle (Average Days) | 97.11 | 243.27 | 159.28 | 138.65 | 159.75 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 136.2 | 67.21 | 69.33 | 162.82 | 119.34 | |||||
Total Debt / Total Capital | 57.66 | 40.2 | 40.94 | 61.95 | 54.41 | |||||
LT Debt/Equity | 123.69 | 61.21 | 52.5 | 126.21 | 106.46 | |||||
Long-Term Debt / Total Capital | 52.37 | 36.61 | 31 | 48.02 | 48.53 | |||||
Total Liabilities / Total Assets | 82.76 | 79.13 | 64.63 | 72.12 | 63.75 | |||||
EBIT / Interest Expense | -5.13 | -3.77 | -5.96 | -3.79 | -3.21 | |||||
EBITDA / Interest Expense | -4.54 | -3.15 | -5.06 | -3.18 | -2.52 | |||||
(EBITDA - Capex) / Interest Expense | -6.31 | -8.59 | -6.6 | -3.79 | -3.1 | |||||
Total Debt / EBITDA | -2.16 | -2.14 | -1.58 | -2.82 | -3.58 | |||||
Net Debt / EBITDA | 2.03 | 4.34 | 1.42 | -1.12 | -0.8 | |||||
Total Debt / (EBITDA - Capex) | -1.56 | -0.79 | -1.21 | -2.36 | -2.91 | |||||
Net Debt / (EBITDA - Capex) | 1.46 | 1.59 | 1.09 | -0.94 | -0.65 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -12.58 | 215.52 | 3.8 | -57.46 | 10.32 | |||||
Gross Profit, 1 Yr. Growth % | -180.34 | -53.87 | 418.87 | -89.63 | -56.03 | |||||
EBITDA, 1 Yr. Growth % | -1.46K | 8.06 | 77 | -22.82 | -18.72 | |||||
EBITA, 1 Yr. Growth % | -4.41K | 14.38 | 77.65 | -21.99 | -12.9 | |||||
EBIT, 1 Yr. Growth % | -4.41K | 14.38 | 77.65 | -21.99 | -12.9 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 3.59K | 14.03 | 95.14 | -29.21 | -87.93 | |||||
Net Income, 1 Yr. Growth % | 3.59K | 14.03 | 95.14 | -29.21 | -87.93 | |||||
Normalized Net Income, 1 Yr. Growth % | -5.44K | 9.75 | 99.87 | -27.47 | -2.98 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 3.45K | 5.94 | 64.96 | -41.03 | -88.51 | |||||
Accounts Receivable, 1 Yr. Growth % | -19.97 | 128.85 | -45.67 | 74.16 | -15.46 | |||||
Inventory, 1 Yr. Growth % | 4.5 | 360.77 | -71.71 | 26.67 | 20.68 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 12.71 | 122.42 | -11.39 | 1.66 | 0.97 | |||||
Total Assets, 1 Yr. Growth % | 69.67 | 81.97 | -23.98 | -25.96 | 8.69 | |||||
Tangible Book Value, 1 Yr. Growth % | -54.09 | 218.76 | 38.02 | -46.01 | 51.18 | |||||
Common Equity, 1 Yr. Growth % | -42.72 | 120.33 | 28.85 | -41.65 | 41.33 | |||||
Cash From Operations, 1 Yr. Growth % | 2.39K | -44.17 | -419.04 | -17.36 | -66.85 | |||||
Capital Expenditures, 1 Yr. Growth % | 80.31 | 387.06 | -68.29 | -51.34 | -2.57 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -654.7 | -173.24 | 258.17 | 40.91 | -59.49 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -855.9 | -146.95 | 352.26 | 42.66 | -64.26 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -1.21 | 66.08 | 80.97 | -33.55 | -31.49 | |||||
Gross Profit, 2 Yr. CAGR % | -18.96 | -39.12 | 54.71 | -26.65 | -78.65 | |||||
EBITDA, 2 Yr. CAGR % | 136.44 | 140.7 | 46.96 | 24.28 | -20.8 | |||||
EBITA, 2 Yr. CAGR % | 196.52 | 636.17 | 42.54 | 24.2 | -17.57 | |||||
EBIT, 2 Yr. CAGR % | 196.52 | 636.17 | 42.54 | 17.62 | -17.57 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 344.16 | 548.86 | 49.17 | 17.53 | -70.76 | |||||
Net Income, 2 Yr. CAGR % | 344.16 | 548.86 | 49.17 | 17.53 | -70.76 | |||||
Normalized Net Income, 2 Yr. CAGR % | 340.88 | 704.05 | 48.11 | 20.32 | -16.12 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 321.31 | 513.27 | 32.2 | -1.37 | -73.97 | |||||
Accounts Receivable, 2 Yr. CAGR % | 30.7 | 35.34 | 11.51 | -2.73 | 21.34 | |||||
Inventory, 2 Yr. CAGR % | 8.86 | 119.44 | 14.17 | -40.14 | 23.64 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 43.42 | 58.34 | 40.39 | -5.09 | 1.31 | |||||
Total Assets, 2 Yr. CAGR % | 39.77 | 75.71 | 17.62 | -24.98 | -10.29 | |||||
Tangible Book Value, 2 Yr. CAGR % | -33.97 | 20.98 | 109.75 | -13.68 | -9.66 | |||||
Common Equity, 2 Yr. CAGR % | -26.47 | 12.34 | 68.49 | -13.29 | -9.19 | |||||
Cash From Operations, 2 Yr. CAGR % | 190.64 | 272.94 | 33.46 | 62.37 | -47.66 | |||||
Capital Expenditures, 2 Yr. CAGR % | 156.69 | 196.35 | 24.28 | -60.72 | -31.15 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 98.64 | 99.68 | 61.97 | 124.55 | -27.54 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 94.39 | 86.54 | 45.71 | 153.88 | -31.79 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 1.57 | 45.49 | 42 | 11.69 | -21.31 | |||||
Gross Profit, 3 Yr. CAGR % | -7.52 | -32.84 | 24.35 | -37.16 | -38.16 | |||||
EBITDA, 3 Yr. CAGR % | 157.95 | 83.07 | 117.26 | 18.49 | 7.88 | |||||
EBITA, 3 Yr. CAGR % | 422.21 | 116.89 | 358.32 | 16.53 | 10.35 | |||||
EBIT, 3 Yr. CAGR % | 422.21 | 116.89 | 358.32 | 16.53 | 6.41 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 77.67 | 182.29 | 334.72 | 16.35 | -44.95 | |||||
Net Income, 3 Yr. CAGR % | 77.67 | 182.29 | 334.72 | 16.35 | -44.95 | |||||
Normalized Net Income, 3 Yr. CAGR % | 93.64 | 178.47 | 405.56 | 16.69 | 11.99 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 67.9 | 165.92 | 295.88 | 1.01 | -51.83 | |||||
Accounts Receivable, 3 Yr. CAGR % | 2.96 | 57.53 | -0.16 | 29.37 | -7.17 | |||||
Inventory, 3 Yr. CAGR % | 10.56 | 76.09 | 10.85 | 18.19 | -24.38 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 26.76 | 66.01 | 30.48 | 26.07 | -3.11 | |||||
Total Assets, 3 Yr. CAGR % | 33.37 | 52.62 | 32.9 | 0.8 | -15.11 | |||||
Tangible Book Value, 3 Yr. CAGR % | -2.17 | 11.59 | 26.41 | 33.42 | 4.05 | |||||
Common Equity, 3 Yr. CAGR % | -5.82 | 6.01 | 17.6 | 18.32 | 2.04 | |||||
Cash From Operations, 3 Yr. CAGR % | 120.61 | 67.7 | 254.03 | 13.75 | -4.39 | |||||
Capital Expenditures, 3 Yr. CAGR % | 87.12 | 217.78 | 40.69 | -9.08 | -46.83 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 71.45 | 41.99 | 142.62 | 54.57 | 29.41 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 63.41 | 20.71 | 150.6 | 44.64 | 34.91 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 5.77 | 28.88 | 27.97 | 6.34 | 6.09 | |||||
Gross Profit, 5 Yr. CAGR % | 20.91 | -15.38 | 13.61 | -30.43 | -38.54 | |||||
EBITDA, 5 Yr. CAGR % | 26.14 | 66.36 | 101.65 | 52.93 | 45.05 | |||||
EBITA, 5 Yr. CAGR % | 22.52 | 50.31 | 211.56 | 69.8 | 130.67 | |||||
EBIT, 5 Yr. CAGR % | 22.52 | 50.31 | 211.56 | 69.8 | 130.67 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 25.58 | 8.34 | 65.67 | 98.83 | 47.67 | |||||
Net Income, 5 Yr. CAGR % | 25.58 | 8.34 | 65.67 | 98.83 | 47.67 | |||||
Normalized Net Income, 5 Yr. CAGR % | 14.21 | 37.81 | 74.38 | 99.07 | 146.38 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 20.16 | 2.69 | 52.59 | 78.84 | 33.26 | |||||
Accounts Receivable, 5 Yr. CAGR % | 4.07 | 21.08 | 6.29 | 29.9 | 7.94 | |||||
Inventory, 5 Yr. CAGR % | 0.18 | 40.46 | 11.99 | 14.37 | 15.8 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 12.99 | 34.81 | 32.04 | 32.74 | 17.92 | |||||
Total Assets, 5 Yr. CAGR % | 10.29 | 31.62 | 26.83 | 14.88 | 13.56 | |||||
Tangible Book Value, 5 Yr. CAGR % | -2.63 | 25.73 | 32.73 | 0.7 | 10.52 | |||||
Common Equity, 5 Yr. CAGR % | -11.71 | 11.26 | 18.86 | -2.18 | 6.05 | |||||
Cash From Operations, 5 Yr. CAGR % | 47.35 | 63.88 | 80.43 | 65.55 | 64.8 | |||||
Capital Expenditures, 5 Yr. CAGR % | 59.16 | 120.79 | 58.87 | 37.7 | 5.71 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 0.81 | 11.02 | 67.27 | 70.56 | 53.93 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 5.92 | 0.88 | 55.82 | 62.52 | 53.58 |
- Stock Market
- Equities
- VLA Stock
- Financials Valneva
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















